Medical grade devices, digital biosensors, consumer grade devices, and wearables. These innovative approaches and technologies have the potential to transform clinical trials. By moving beyond buzzwords and into action, deploying remote devices with sound scientific practices allows for better data collection and transparency, accelerated timelines, reduced costs and improved clinical trial outcomes for sponsors and patients. In this insight brief, leaders from IQVIA, Sunovion Pharmaceuticals and Philips Healthcare explore the challenges and opportunities this new digital health paradigm brings, and how sponsors can move beyond buzzwords and into action.
The digital health ecosystem is expanding rapidly to include a wide range of apps, wearables, biometric sensors, connected virtual assistants and web-based interactive programs (Figure 1). The global healthcare wearable devices sector recorded sales of $5.1bn in 2015 and this is forecast to reach $18.9bn in 2020; medical and clinical grade wearables are expected to grow at a compound annual growth rate (CAGR) of 32.9 percent.
Over 318,000 health apps and 340 consumer wearable devices are available worldwide, with over 200 health apps being added each day.2,3 These tools can help clinical trial sponsors ensure they receive objective, timely and accurate data.
Terminology for these digital health solutions falls into four main categories: medical grade devices, digital biosensors, consumer grade devices, and wearables